AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15558082 — intervention group
Group type: COMPARATOR
Intervention: Staff assessment of patients' functional limitations
Number of subjects: 29
Study 15558082 — intervention group
Group type: COMPARATOR
Intervention: Staff assessment of patients' role problems
Number of subjects: 29
Study 15558082 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between patient and staff ratings
Number of subjects: 29
Study 12413331 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated blood collection device (spring-loaded lance)
Number of subjects: 134
Study 12413331 — intervention group
Group type: COMPARATOR
Intervention: Manual lance
Number of subjects: 134
Study 10215948 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic HIV-positive haemophiliacs
Number of subjects: 38
Study 10215948 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative haemophiliacs
Number of subjects: 38
Study 8746073 — intervention group
Group type: EXPERIMENTAL
Intervention: ipriflavone (IP)
Number of subjects: 40
Study 8746073 — intervention group
Group type: COMPARATOR
Intervention: salmon calcitonin (sCT)
Number of subjects: 40
Study 2612203 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin plus clavulanic acid (250 or 500 mg amoxycillin and 62.5 or 125 mg clavulanic acid) 3-times daily
Number of subjects: 100
Study 2612203 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (250 or 500 mg) 3-times daily
Number of subjects: 100
Study 338197 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 74,917 (0.5 mg in each nostril four times a day)
Number of subjects: 24
Study 338197 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 24
Study 31461393 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Dentin Sealing (IDS)
Number of subjects: 60
Study 31461393 — intervention group
Group type: COMPARATOR
Intervention: Delayed Dentin Sealing (DDS)
Number of subjects: 60
Study 28661696 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction (DB group)
Number of subjects: 90
Study 28661696 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bundle ACL reconstruction with bioabsorbable screw fixation (SBB group)
Number of subjects: 90
Study 28661696 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bundle ACL reconstruction with metallic screw fixation (SBM group)
Number of subjects: 90
Study 28661696 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 90
Study 28661696 — intervention group
Group type: COMPARATOR
Intervention: Patients with longest delay from injury to reconstruction
Number of subjects: 90
Study 28661696 — intervention group
Group type: COMPARATOR
Intervention: Patients who underwent partial meniscal resection
Number of subjects: 90
Study 26203094 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 2400
Study 26203094 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 2400
Study 26203094 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc + Multivitamin supplementation
Number of subjects: 2400
Study 26203094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2400
Study 23757427 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) insulin delivery
Number of subjects: 12
Study 23757427 — intervention group
Group type: COMPARATOR
Intervention: Open-loop (OL) control
Number of subjects: 12
Study 21565820 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls prevention program (intervention group)
Number of subjects: 204
Study 21565820 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204
Study 19620514 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow sodium
Number of subjects: 169
Study 19620514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 17482982 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (100 mg/day)
Number of subjects: 264
Study 17482982 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B (3 mg/kg per day)
Number of subjects: 264
Study 17482982 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 264
Study 17482982 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B
Number of subjects: 264
Study 15501783 — intervention group
Group type: EXPERIMENTAL
Intervention: 20- or 50-microg dose of alum-adsorbed ICC-1132 administered intramuscularly at 0, 2, and 6 months
Number of subjects: 20
Study 15501783 — intervention group
Group type: EXPERIMENTAL
Intervention: ICC-1132-alum
Number of subjects: 20
Study 11675958 — intervention group
Group type: EXPERIMENTAL
Intervention: Arotinolol 10-20 mg twice daily for 4 weeks
Number of subjects: 47
Study 9136230 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention utilizing opinion leaders and educational strategies over 15 months.
Number of subjects: 6
Study 9136230 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in at least one intervention program.
Number of subjects: 6
Study 9136230 — intervention group
Group type: COMPARATOR
Intervention: Control communities (not specified in detail).
Number of subjects: 6
Study 7701226 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized aerosol hyperthermia (AH) with aerosol of 43 degrees C
Number of subjects: 57
Study 7701226 — intervention group
Group type: COMPARATOR
Intervention: Placebo device (PH) with aerosol of 32 degrees C
Number of subjects: 57
Study 7701226 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized aerosol hyperthermia (AH)
Number of subjects: 57
Study 7701226 — intervention group
Group type: COMPARATOR
Intervention: Placebo device (PH)
Number of subjects: 57
Study 3542183 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (Intron A, Schering Corp., Kenilworth, NJ) 2 X 10(6) U/m2 subcutaneously, three times a week for 1 year
Number of subjects: 212
Study 3542183 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa‐2b (Intron A, Schering Corp., Kenilworth, NJ) continued for 6 months
Number of subjects: 212
Study 29142030 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA) plus Methotrexate (MTX)
Number of subjects: 180
Study 29142030 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Methotrexate (MTX)
Number of subjects: 180
Study 27820670 — intervention group
Group type: EXPERIMENTAL
Intervention: Newcomer and traveler surveillance and treatment program in addition to annual mass drug administration (MDA)
Number of subjects: 5200
Study 27820670 — intervention group
Group type: COMPARATOR
Intervention: Usual practice communities receiving MDA only
Number of subjects: 5200
Study 27820670 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population with TF
Number of subjects: 5200
Study 27820670 — intervention group
Group type: EXPERIMENTAL
Intervention: Households without a bicycle
Number of subjects: 5200
Study 27820670 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing child's age
Number of subjects: 5200
Study 27820670 — intervention group
Group type: EXPERIMENTAL
Intervention: Households >30 minutes from water
Number of subjects: 5200
Study 27820670 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing years of education
Number of subjects: 5200
Study 25621884 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 μg of A/H1N1 antigen formulated with 50% MF59 (3.75_halfMF59)
Number of subjects: 666
Study 25621884 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 μg of A/H1N1 antigen formulated with 100% MF59 (7.5_fullMF59)
Number of subjects: 666
Study 25621884 — intervention group
Group type: COMPARATOR
Intervention: Nonadjuvanted 15 μg A/H1N1 antigen
Number of subjects: 666
Study 25621884 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5_fullMF59
Number of subjects: 666
Study 25621884 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75_halfMF59
Number of subjects: 666
Study 23086524 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid weight loss (RWL) preparation with very low calorie diet
Number of subjects: 28
Study 21905025 — intervention group
Group type: EXPERIMENTAL
Intervention: Written disclosure
Number of subjects: 214
Study 21905025 — intervention group
Group type: EXPERIMENTAL
Intervention: Private spoken disclosure
Number of subjects: 214
Study 21905025 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking to a passive listener
Number of subjects: 214
Study 21905025 — intervention group
Group type: EXPERIMENTAL
Intervention: Talking to an active facilitator
Number of subjects: 214
Study 21905025 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 214
Study 21905025 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (disclosure and control)
Number of subjects: 214
Study 18238794 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone patches (150 microg)
Number of subjects: 34
Study 18238794 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 34
Study 16603244 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% ophthalmic solution
Number of subjects: 46
Study 16603244 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin 0.3% ophthalmic solution
Number of subjects: 46
Study 15537995 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Therapy (CIT) for 2 weeks
Number of subjects: 10
Study 15537995 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment group (no therapy for 2 weeks)
Number of subjects: 10
Study 11095450 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) at a mean dose of 6.7 microg/kg x day (1.6 IU/day)
Number of subjects: 11
Study 9274583 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based psychosocial nursing intervention (n = 692)
Number of subjects: 1376
Study 9274583 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 684)
Number of subjects: 1376
Study 8036599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospidin (total dose 3.0‐9.8 g)
Number of subjects: 40
Study 8036599 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 40
Study 3548485 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine in 7.5% glucose (LG)
Number of subjects: 40
Study 3548485 — intervention group
Group type: COMPARATOR
Intervention: 5% meperidine in water
Number of subjects: 40
Study 29132073 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message-based maintenance intervention with standardized messages targeting emotion regulation
Number of subjects: 226
Study 29132073 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message-based maintenance intervention with individualized messages
Number of subjects: 226
Study 29132073 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 226
Study 27425565 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Minds program (acceptance and commitment therapy combined with positive psychology)
Number of subjects: 267
Study 23895414 — intervention group
Group type: EXPERIMENTAL
Intervention: LED group (treadmill training with phototherapy)
Number of subjects: 30
Study 23895414 — intervention group
Group type: COMPARATOR
Intervention: Exercise group (treadmill training only)
Number of subjects: 30
Study 23895414 — intervention group
Group type: COMPARATOR
Intervention: Sedentary group (no training or phototherapy)
Number of subjects: 30
Study 22732747 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-step critical pathway
Number of subjects: 401
Study 22732747 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 401
Study 20557379 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls prevention programme interventions based on assessment findings
Number of subjects: 712
Study 20557379 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 712
Study 18696749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladistic methods based on Templeton's algorithm (TA)
Number of subjects: 0
Study 18696749 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladistic methods based on Durrant et al.'s hierarchical clustering
Number of subjects: 0
Study 16180634 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-oxide eugenol
Number of subjects: 11
Study 12765670 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein disease-specific enteral formula
Number of subjects: 50
Study 12765670 — intervention group
Group type: COMPARATOR
Intervention: High-protein enteral formula (control)
Number of subjects: 50
Study 9873844 — intervention group
Group type: EXPERIMENTAL
Intervention: BPL 8Y factor VIII concentrate
Number of subjects: 33
Study 7847302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg q.i.d.)
Number of subjects: 16
Study 7847302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2688884 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy
Number of subjects: 0
Study 30755573 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (Group A, n=34)
Number of subjects: 102
Study 30755573 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (Group B, n=34)
Number of subjects: 102
Study 30755573 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (Group C, n=34)
Number of subjects: 102
Study 28965164 — intervention group
Group type: EXPERIMENTAL
Intervention: ACV preservation (group 1) - one rectus muscle operated (group A)
Number of subjects: 73
Study 28965164 — intervention group
Group type: EXPERIMENTAL
Intervention: ACV preservation (group 1) - two rectus muscles operated (group B)
Number of subjects: 73
Study 28965164 — intervention group
Group type: COMPARATOR
Intervention: No ACV preservation (group 2) - one rectus muscle operated (group C)
Number of subjects: 73
Study 28965164 — intervention group
Group type: COMPARATOR
Intervention: No ACV preservation (group 2) - two rectus muscles operated (group D)
Number of subjects: 73
Study 25345750 — intervention group
Group type: EXPERIMENTAL
Intervention: Xalatan
Number of subjects: 19
Study 25345750 — intervention group
Group type: COMPARATOR
Intervention: Glautan
Number of subjects: 19
Study 23955106 — intervention group
Group type: EXPERIMENTAL
Intervention: d-chlorpheniramine 4 mg
Number of subjects: 27
Study 23955106 — intervention group
Group type: COMPARATOR
Intervention: d-chlorpheniramine 2 mg
Number of subjects: 27
Study 23955106 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study 21422197 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin administration (replacement doses)
Number of subjects: 52
Study 21422197 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin administration (pharmacological doses)
Number of subjects: 52
Study 21422197 — intervention group
Group type: COMPARATOR
Intervention: Leptin replacement in women with hypothalamic amenorrhea
Number of subjects: 52
Study 21422197 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration in women with hypothalamic amenorrhea
Number of subjects: 52
Study 21422197 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute starvation
Number of subjects: 52
Study 19411525 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.2 mg)
Number of subjects: 14
Study 19411525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 17275695 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin administration (0.6 mg)
Number of subjects: 45
Study 15851825 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (3 sessions per week for 9 weeks)
Number of subjects: 42
Study 15851825 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study 11514686 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg inhaled salbutamol
Number of subjects: 12
Study 11514686 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 microg inhaled salbutamol
Number of subjects: 12
Study 11514686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9764337 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine (100 mg/kg/d infused for a total of 72 h)
Number of subjects: 352
Study 9764337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 9764337 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Number of subjects: 352
Study 7512124 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth factors (GFs) including G-CSF (7.5 micrograms/kg/d) and GM-CSF (2.5 micrograms/kg/d) administered as a 2-hour intravenous infusion twice per day until neutrophil count > 1,500/microL
Number of subjects: 37
Study 7512124 — intervention group
Group type: COMPARATOR
Intervention: No growth factors (Control)
Number of subjects: 37
Study 7512124 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth factors (GFs)
Number of subjects: 37
Study 3948703 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin (0.2‐0.4 mg/kg bodyweight)
Number of subjects: 12
Study 29696404 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-to-child transmission (MTCT) of HIV prevention program (Option A - infant prophylaxis)
Number of subjects: 0
Study 27584088 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based follow-up
Number of subjects: 1246
Study 27584088 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based follow-up
Number of subjects: 1246
Study 27584088 — intervention group
Group type: COMPARATOR
Intervention: Passive or needs-based follow-up
Number of subjects: 1246
Study 27584088 — intervention group
Group type: EXPERIMENTAL
Intervention: Active follow-up (home-based + telephone-based)
Number of subjects: 1246
Study 27584088 — intervention group
Group type: COMPARATOR
Intervention: Active vs Passive follow-up
Number of subjects: 1246
Study 27584088 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based vs Home-based follow-up
Number of subjects: 1246
Study 24718568 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring arm (platelet function monitoring with drug adjustment)
Number of subjects: 2440
Study 24718568 — intervention group
Group type: COMPARATOR
Intervention: Conventional arm (no monitoring, no drug or dose changes)
Number of subjects: 2440
Study 24718568 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring arm
Number of subjects: 2440
Study 24718568 — intervention group
Group type: COMPARATOR
Intervention: Conventional arm
Number of subjects: 2440
Study 23316296 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher resting heart rate
Number of subjects: 11140
Study 20196974 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.6 g marine n‐3 PUFA/day
Number of subjects: 60
Study 20196974 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g marine n‐3 PUFA/day
Number of subjects: 60
Study 20196974 — intervention group
Group type: COMPARATOR
Intervention: 6.6 g olive oil (control)
Number of subjects: 60
Study 18779540 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa plus aerobic exercise training (DEX; n = 26)
Number of subjects: 55
Study 18779540 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa alone (DAL; n = 29)
Number of subjects: 55
Study 18044706 — intervention group
Group type: EXPERIMENTAL
Intervention: STN-DBS and levodopa (ON(MED)/ON(STIM))
Number of subjects: 8
Study 18044706 — intervention group
Group type: EXPERIMENTAL
Intervention: STN-DBS only (OFF(MED)/ON(STIM))
Number of subjects: 8
Study 18044706 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa only (ON(MED)/OFF(STIM))
Number of subjects: 8
Study 18044706 — intervention group
Group type: EXPERIMENTAL
Intervention: without STN-DBS/levodopa (OFF(MED)/OFF(STIM))
Number of subjects: 8
Study 18044706 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 volunteers)
Number of subjects: 8
Study 15179022 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg)
Number of subjects: 293
Study 15179022 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR (75-150 mg)
Number of subjects: 293
Study 15179022 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 293
Study 15179022 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR
Number of subjects: 293
Study 12026269 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom intervention
Number of subjects: 3
Study 12026269 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-classroom intervention
Number of subjects: 3
Study 12026269 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study 9302488 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation (5 g creatine plus 1 g glucose X 5 doses daily for 7 days)
Number of subjects: 9
Study 9302488 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl) treatment (6 g glucose X 5 doses daily for 7 days)
Number of subjects: 9
Study 9302488 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation
Number of subjects: 9
Study 9302488 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl) treatment
Number of subjects: 9
Study 8171738 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 subcutaneous therapy (3 million IU twice/daily for 5 days/week for 6 weeks)
Number of subjects: 30
Study 8171738 — intervention group
Group type: COMPARATOR
Intervention: IL-2 plus interferon-alpha (5 million U/m2 subcutaneously thrice weekly)
Number of subjects: 30
Study 8171738 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 subcutaneous therapy
Number of subjects: 30
Study 8171738 — intervention group
Group type: COMPARATOR
Intervention: IL-2 plus interferon-alpha
Number of subjects: 30
Study 3534842 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-50 mg hydrochlorothiazide and 50-100 mg of triamterene daily (active treatment group)
Number of subjects: 507
Study 3534842 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 507
Study 3534842 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group
Number of subjects: 507
Study 3534842 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 507
Study 31177888 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h urine protein excretion
Number of subjects: 118
Study 31177888 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant and 24-h urine protein/creatinine (P/Cr) and albumin/creatinine (A/Cr) ratios
Number of subjects: 118
Study 31177888 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h urine P/Cr ratio
Number of subjects: 118
Study 28099502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (21 days of a 28 days cycle)
Number of subjects: 21